Francis E. Odonnell, Jr. Sells 8,000 Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Stock

Share on StockTwits

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.86, for a total value of $54,880.00. Following the sale, the director now owns 564,754 shares in the company, valued at approximately $3,874,212.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

BDSI stock traded up $0.04 during trading on Friday, hitting $6.53. The company had a trading volume of 11,255 shares, compared to its average volume of 975,548. The firm has a market cap of $605.16 million, a PE ratio of -8.93 and a beta of 0.49. BioDelivery Sciences International, Inc. has a 1-year low of $2.80 and a 1-year high of $7.01. The firm has a 50-day moving average price of $5.97 and a 200-day moving average price of $4.76. The company has a quick ratio of 2.02, a current ratio of 2.25 and a debt-to-equity ratio of 0.86.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.34. The firm had revenue of $30.31 million for the quarter, compared to analysts’ expectations of $28.86 million. BioDelivery Sciences International had a negative return on equity of 8.80% and a negative net margin of 22.11%. Sell-side analysts anticipate that BioDelivery Sciences International, Inc. will post 0.02 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of BDSI. BlackRock Inc. increased its holdings in shares of BioDelivery Sciences International by 277.2% during the 2nd quarter. BlackRock Inc. now owns 5,498,457 shares of the specialty pharmaceutical company’s stock worth $25,568,000 after buying an additional 4,040,621 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of BioDelivery Sciences International by 30.5% in the second quarter. Vanguard Group Inc. now owns 3,395,428 shares of the specialty pharmaceutical company’s stock valued at $15,788,000 after purchasing an additional 793,179 shares during the period. Stonepine Capital Management LLC increased its stake in shares of BioDelivery Sciences International by 79.6% in the second quarter. Stonepine Capital Management LLC now owns 2,764,475 shares of the specialty pharmaceutical company’s stock valued at $12,855,000 after purchasing an additional 1,225,038 shares during the period. Emerald Advisers LLC increased its stake in shares of BioDelivery Sciences International by 11.4% in the third quarter. Emerald Advisers LLC now owns 2,084,685 shares of the specialty pharmaceutical company’s stock valued at $8,777,000 after purchasing an additional 212,553 shares during the period. Finally, Emerald Mutual Fund Advisers Trust increased its stake in shares of BioDelivery Sciences International by 13.8% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,944,531 shares of the specialty pharmaceutical company’s stock valued at $8,186,000 after purchasing an additional 236,254 shares during the period. Hedge funds and other institutional investors own 69.44% of the company’s stock.

A number of analysts have recently commented on BDSI shares. William Blair reiterated a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. ValuEngine upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Tuesday. BidaskClub cut BioDelivery Sciences International from a “strong-buy” rating to a “buy” rating in a research report on Friday. TheStreet upgraded BioDelivery Sciences International from a “d” rating to a “c” rating in a research report on Friday, November 22nd. Finally, LADENBURG THALM/SH SH lifted their target price on BioDelivery Sciences International from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $6.50.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: What is diluted earnings per share (Diluted EPS)?

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Janney Montgomery Scott LLC Purchases 22,288 Shares of Colgate-Palmolive
Janney Montgomery Scott LLC Purchases 22,288 Shares of Colgate-Palmolive
Janney Montgomery Scott LLC Boosts Stake in Vanguard Large-Cap ETF
Janney Montgomery Scott LLC Boosts Stake in Vanguard Large-Cap ETF
Janney Montgomery Scott LLC Trims Stock Position in Emerson Electric Co.
Janney Montgomery Scott LLC Trims Stock Position in Emerson Electric Co.
Janney Montgomery Scott LLC Has $13.87 Million Stock Holdings in First Trust Preferred Securities and Income ETF
Janney Montgomery Scott LLC Has $13.87 Million Stock Holdings in First Trust Preferred Securities and Income ETF
Squar Milner Financial Services LLC Has $91,000 Stock Position in SPDR Wells Fargo Preferred Stock ETF
Squar Milner Financial Services LLC Has $91,000 Stock Position in SPDR Wells Fargo Preferred Stock ETF
Janney Montgomery Scott LLC Acquires 8,875 Shares of iShares Select Dividend ETF
Janney Montgomery Scott LLC Acquires 8,875 Shares of iShares Select Dividend ETF


© 2006-2020 Ticker Report